Biopharmaceuticals Market Growth: Worth $700Bn by 2028 Led by Monoclonal Antibodies Held Market Share of 48.42% in 2022 | The Insight Partners
March 23, 2023 08:46 ET
|
The Insight Partners
New York, March 23, 2023 (GLOBE NEWSWIRE) -- According to The Insight Partners, “Biopharmaceuticals Market Size, Share, Trends, Growth and Report Forecasts to 2028 - COVID-19 Impact and Global...
Obstetric and Neonatal Professionals Must Work More Closely with Pregnant People to Identify Liver Diseases Early
February 01, 2023 11:11 ET
|
Global Liver Institute
Washington, D.C., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Global Liver Institute (GLI) launches its third annual #RareAware campaign today to raise awareness of and build resources for liver health...
Rare Diseases Treatment Market to Rise High at US$346.5 Bn by 2029 End, Projects Fairfield Market Research
October 03, 2022 09:33 ET
|
Fairfield Consultancy Services OPC Pvt Ltd
London, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Projected to exhibit robust 10.4% growth between 2022 and 2029, global rare diseases treatment market will possibly reach the revenue of around US$346.5 Bn...
The Oligonucleotide Therapeutics Society's Highly Anticipated Annual Meeting Returns in Person This Year
September 04, 2022 11:00 ET
|
Oligonucleotide Therapeutics Society
SAN DIEGO, Sept. 04, 2022 (GLOBE NEWSWIRE) -- OTS is pleased to announce that, after two years of meeting virtually, the 18th Annual Oligo Meeting will include a robust in-person program live from...
American Kidney Fund Survey Underscores Need to Expand Testing for Chronic Kidney Disease and Increase Awareness of Rare Kidney Diseases
April 07, 2022 09:00 ET
|
American Kidney Fund
ROCKVILLE, Md., April 07, 2022 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) today released survey findings that provide new insights on the level of awareness among health care providers about...
FDA approves Novartis Vijoice® (alpelisib) as first and only treatment for select patients with PIK3CA-Related Overgrowth Spectrum (PROS)
April 05, 2022 20:29 ET
|
Novartis Pharma AG
Vijoice is first approved treatment to specifically address the root cause of PROS conditions in select patients 2 years of age and older1 PROS is a spectrum of rare conditions and is characterized by...
Global Liver Institute Leads Second Annual Rare Liver Diseases Month
February 01, 2022 10:41 ET
|
Global Liver Institute
Washington, DC, USA, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Global Liver Institute (GLI), a patient-led liver health nonprofit operating globally, is proud to announce today the launch of its second...
CURATIVE BIOTECHNOLOGY ANNOUNCES DR. CATHERINE SOHN AS SPECIAL ADVISOR TO BOARD AND CEO
October 12, 2021 10:12 ET
|
Curative Biotechnology, Inc.
Dr. Sohn to Oversee Development of Next Gen COVID-19 Vaccine to Treat Kidney Failure Patients, Late-Stage Rabies Therapeutic and Age-related Macular Degeneration Boca Raton, FL, Oct. 12, 2021 ...
The Oligonucleotide Therapeutics Society Celebrates Another Remarkable Annual Meeting
October 09, 2021 12:00 ET
|
The Oligonucleotide Therapeutics Society
SAN DIEGO, Oct. 09, 2021 (GLOBE NEWSWIRE) -- The Oligonucleotide Therapeutics Society's 17th Annual Meeting was held virtually the second year in a row and was once again phenomenally successful....
Fortress Biotech Announces Receipt of Notice of Option Exercise from AstraZeneca to Fully Acquire Caelum Biosciences, a Company Founded by Fortress Biotech
September 29, 2021 07:00 ET
|
Fortress Biotech, Inc.
Option exercise triggers upfront payment of approximately $150 million to Caelum shareholders, of which approximately $64 million is payable to Fortress Biotech1 AstraZeneca intends to advance and...